News

21st Century Cures: What's Next for Colorado?

Thursday, December 22, 2016

DENVER, Colo. – The biomedical research industry supports more than seven million jobs and contributes $69 billion to the U.S. GDP. In 2015, with a budget of over $30 billion, the National Institutes of Health (NIH) funded more than 300,000 scientists to support groundbreaking research around the globe. 

Clovis's ovarian cancer drug wins accelerated FDA approval

Tuesday, December 20, 2016

Via Reuters  

Colorado BioScience Association Recaps Growth Year for State’s Life Science Sector

Thursday, December 15, 2016

For Immediate Release: December 15, 2016
 

​CBSA Celebrates the passage of the 21st Century Cures Act

Wednesday, December 07, 2016

CBSA Celebrates the passage of the 21st Century Cures Act 

Biodesix named Innovative Company of the Year; Innosphere selected as Incubabor/Accelerator of the Year

Wednesday, December 07, 2016

Innovative Company of the Year  

Symbios Technologies Announces Five-Year Master Research and Development Agreement with Colorado State University

Tuesday, December 06, 2016

Symbios Technologies, Inc., a world-leading developer of dynamic aqueous plasma technology platforms, announced today that the company has engaged in a collaborative research partnership with Colorado State University (CSU) through a five-year Master Research and Development Agreement (MRDA) with the CSU Office of the Vice President for Research. This agreement is designed to further the commercialization of the company’s technology and the mission of CSU as a modern land-grant university. 

ArcherDX launches Immune Repertoire Sequencing Assays at ASH 2016

Thursday, December 01, 2016

ArcherDX, the leader in NGS-based fusion assays, today announced the release of the Archer® Immunoverse™ immune repertoire sequencing assays. These targeted sequencing assays are the latest addition to the Archer product portfolio that now includes the Reveal ctDNA™ 28 assay for liquid biopsy research, as well as the VariantPlex™ and FusionPlex® assays for SNV/indel, copy number variation (CNV) and gene fusion detection. ArcherDX plans to reveal Immunoverse at the 58th American Society of Hematology Annual Meeting, which starts this weekend in San Diego, CA.